Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Bullboard Posts
Comment by fredgoodwinsonon Jan 05, 2020 6:38pm
145 Views
Post# 30520448

RE:RE:UUTUC

RE:RE:UUTUC

Justforfun - please see below the definition of a Complete Response as has been agreed with the Regulatory Authorities for Phase II. The Company discussed this with them at length in the light of Phase IB and I hope that the last of the three categories of CR definition will finally put your mind at rest:

 

The Complete Response will be evaluated at 90 days`post-treatment with duration evaluated at 360 days`post-treatment.

 

Complete Response is defined as:

 

  • Negative cystoscopy and negative urine cytology; or

 

  • Positive cystoscopy with biopsy-proven benign or low-grade NMIBC and negative cytology; or

 

  • Negative cystoscopy with malignant urine cytology if cancer is found in the upper tract or prostatic urethra and random bladder biopsies are negative.

 

 

This will allow for the possibility of a Complete Response being defined in the bladder even if cancer persists elsewhere. Note that the CR is defined at 90 days` - i.e. before the second treatment which itself may or may not serve to systemically address cancer remote from the bladder.

Bullboard Posts